EUS-guided gall bladder drainage with a lumen-apposing metal stent: a prospective long-term evaluation

Daisy Walter, Anthony Y Teoh, Takao Itoi, Manuel Pérez-Miranda, Alberto Larghi, Andres Sanchez-Yague, Peter D Siersema, Frank P Vleggaar

Endoscopic ultrasound-guided gall bladder drainage (EUS-GBD) has been shown to be comparable with percutaneous gall bladder drainage (PTGBD) in terms of technical feasibility and clinical efficacy for the treatment of acute cholecystitis in high-risk surgical patients. However, a potential serious complication of this technique is air or bile leakage into the peritoneal cavity, since insertion of a drain or plastic stent requires a fistula tract with a diameter larger than the diameter of the inserted drain or stent. Therefore, a specifically designed lumen-apposing metal stents (LAMSSs) has been developed for transenteric drainage and successfully tested in animal models. Preliminary clinical experience with LAMSSs for drainage of peri-pancreatic fluid collections (PFCSSs) appears to be consistent with anchoring features tested in animal models. However, reports on the use of LAMSSs for gall bladder drainage are limited to case reports and small case series without long-term follow-up.

We performed a multicentre, prospective study to determine the feasibility and safety of the use of LAMSSs for EUS-GBD in high-risk surgical patients with acute cholecystitis. A total of 30 patients were included. Technical success was achieved in 27 of 30 patients (90%) (figure 1) and clinical success in 26 of 27 patients (96%). Two of 27 patients (7%) developed recurrent cholecystitis due to LAMSS obstruction. Successful LAMSS removal was performed in 15 of 30 patients (50%) after a mean of 91 days (SD±24 days). In 15 patients (50%), LAMSS removal was performed because of death (n=5), significant tissue overgrowth (n=2) or other causes (n=8). Mean follow-up was 298 days (SD±82 days) for all patients and 364 days (SD±82 days) for the patients alive at the end of the study. A total of 15 serious adverse events (SAEs) (50%) were reported, including four that were possibly stent-related or procedure-related (13%). Overall mortality was 2.3% (7/30), with 30-day mortality of 17% (5/30) (find more details in online supplementary methods and results).

**COMMENTS**
This study is the first multicentre prospective study on the use of a LAMSS for EUS-GBD in high-risk surgical patients with acute cholecystitis. To date, EUS-GBD using an LAMSS has been described in eight reports including 30 patients, reporting an overall technical success rate of 93%.

This high success rate is most likely an overestimation since the majority of reports included retrospective small case series and case reports, which are prone to publication bias. Technical failures were only reported by de la Serna-Higuera et al who retrospectively evaluated EUS-GBD in 13 patients using the same LAMSS as was used in the present study. These authors reported a technical success rate of 83%, with two technical failures.

In addition, in four patients a second fully covered tubular self-expandable metal stent (SEMS) was inserted through the LAMSS to ensure stent patency and stability, resulting in difficulties with stent placement in 6 of 13 patients (46%) in this study. In our study, technical failures occurred in 3 of 30 patients (10%) and technical problems with LAMSS deployment in another 2 of 30 patients (7%), resulting in an overall technical difficulties rate of 17%. However, in all three patients with technical failures, successful endoscopic drainage was ultimately achieved during the same procedure with placement of an additional stent (figures 1 and 2).

In order to improve technical success, refinement of the current LAMSS and accessories may improve the results of EUS-GBD. The evolution of the LAMSS used in the present study is a new delivery system with electrocautery on the tip, which allows puncture and release of the stent in a single-step procedure, thus decreasing the number of accessories to be exchanged and consequently potentially reducing the frequency of complications. This newly developed device (Hot Axios, Xlumena, Mountain View, California, USA) has already successfully been used for both gall bladder and PFCSS drainage. Furthermore, since the procedure is challenging, even in experienced hands, a learning curve should be anticipated. Because of these considerations, it is our opinion that EUS-GBD should currently only be performed in high-volume experienced centres.

It is known that a mature fistula tract is formed in the porcine model following LAMSS placement after a period of 4–5 weeks. In order to minimise the risk of recurrent cholecystitis and bile leakage, we decided to leave the LAMSS in place for a period of 3 months. A drawback was that we experienced significant tissue overgrowth in three patients (10%) at the time of LAMSS removal that precluded removal in two patients (figure 2). Although a more significant tissue reaction can be expected after a longer stent dwell time, we hypothesise that stent location, either gastric or duodenal, might also influence the degree of tissue overgrowth. The retroperitoneal location of the duodenal results in a more stable tract to the gall bladder as compared
other studies on EUS-GBD using SEMS.\(^7\)\(^5\) Complications, even up to 3 years, has also been reported during a mean stent dwell time of 364 days. Long-term stenting without stent-related complications were observed during a mean stent in place of 1 year. However, large comparative studies are needed to confirm these results, leaving stents, either SEMS or LAMS, permanently in place may likely be considered as an alternative treatment option, which avoids the risks and discomfort associated with a repeat procedure for stent removal.

Furthermore, although gall bladder drainage is most often intended as a bridge to elective surgery, none of the patients in our study turned out to be eligible for elective cholecystectomy mainly due to their ongoing high surgical risk. In order to reduce the risk of recurrent cholecystitis in these patients, permanent drainage is desirable. The advantage of EUS-GBD compared with PTGBD is that long-term stenting does not require an external drainage catheter, which likely may increase patients’ comfort and quality of life.\(^1\)\(^5\)

Safety was closely monitored in our study and all SAEs were reviewed by an independent data safety monitoring board. The 30-day mortality in our study was 17%, which is comparable with the 30-day mortality or in-hospital death of 15.4% after PTGBD. In addition, the 7% stent-related or procedure-related mortality observed in our study is comparable with the 30-day mortality or in-hospital death of 15.4% after PTGBD. In conclusion, we think that EUS-GBD using LAMS is an elegant procedure in high-risk surgical patients with acute cholecystitis when performed by an experienced endoscopist. However, large comparative studies are needed to confirm these promising results, to optimise the technical procedure and to address remaining questions, such as optimal stent dwell time and preferred route of access.

**Acknowledgements** We would like to thank the members of the Data Safety Monitoring Board for their efforts for this study: Dr ECI Consten (gastrointestinal surgeon); Dr EW Steyerberg (professor of medical decision making); Dr R. Timmer (gastroenterologist) and Dr EPA Vonken (interventional radiologist).

**Contributors** DW: literature search, study design, patient inclusion, data collection, data analysis, statistical analysis, data interpretation, drafting of the manuscript and final approval. AYT, TI, MP-M, AL, AS-Y: study design, patient inclusion, data collection, critical revision and final approval of the manuscript. FPV: study design, critical revision and final approval of the manuscript. PDS: study design, critical revision and final approval of the manuscript. PK: critical revision and final approval of the manuscript. FF: study design, patient inclusion, data collection, data interpretation, study supervision, critical revision and final approval of the manuscript.

**Competing interests** TI: Speaker for Xlumena. AL and MP-M: Consultant for Xlumena.

**Ethics approval** Ethical Committee and board of all participating centres.

**Provenance and peer review** Not commissioned; internally peer reviewed.

**REFERENCES**


